Prenalterol

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Prenalterol
Prenalterol.svg
Clinical data
Routes of
administration
Oral, IV
ATC code C01CA13 (WHO)
Legal status
Legal status
  • ℞ (Prescription only)
Identifiers
CAS Number 57526-81-5 N
PubChem (CID) 42396
IUPHAR/BPS 537
ChemSpider 38665 YesY
UNII M4G34404CX YesY
ChEMBL CHEMBL1160714 YesY
ECHA InfoCard 100.055.246
Chemical and physical data
Formula C12H19NO3
Molar mass 225.284 g/mol
3D model (Jmol) Interactive image
 NYesY (what is this?)  (verify)

Prenalterol is a cardiac stimulant which acts as a β1 adrenoreceptor agonist.[1]

Synthesis[edit]

Stereospecific[edit]

Prenalterol interestingly exhibits adrenergic agonist activity in spite of an interposed oxymethylene group. The stereospecific synthesis devised for this molecule relies on the fact that the side chain is very similar in oxidation state to that of a sugar.

Prenalterol synthesis:[2][3]

Condensation of the monobenzyl ether of phenol (1) with the epoxide derived from α-D-glucofuranose[4] affords the glycosylated derivative (3). Hydrolytic removal of the acetonide protecting groups (cf. eg)[5] followed by cleavage of the sugar with periodate gives aldehyde (4). This is reduced to the glycol by means of NaBH4 and the terminal alcohol is converted to the mesylate (5). Displacement of the leaving group with isopropylamine followed by hydrogenolytic removal of the O-benzyl ether affords the β1-adrenergic selective adrenergic agonist prenalterol (6).

Racemic[edit]

Prepns of the racemic mixture: NL 6409883  corresp to H. Köppe et al., U.S. Patent 3,637,852 (1965, 1972 both to Boehringer Ingelheim); NL 301580  corresp to A. F. Crowther, L. H. Smith, U.S. Patent 3,501,769 (1965, 1970 both to ICI);[6]

Further reading[edit]

See also[edit]

References[edit]

  1. ^ Hadfield SE, Slee SJ, Snow HM (1989). "The cardiovascular pharmacology of xamoterol, cicloprolol, prenalterol and pindolol in the anaesthetised dog". Br J Clin Pharmacol. 28 Suppl 1 (Suppl 1): 78S–81S. doi:10.1111/j.1365-2125.1989.tb03580.x. PMC 1379883Freely accessible. PMID 2572262. 
  2. ^ K. A. Jaeggi, H. Schroeter, and F. Ostermayer, DE 2503968 ; Chem. Abstr. 84, 5322 (1976).
  3. ^ corresp to U.S. Patent 3,978,041 and U.S. Patent 4,049,797 (1975, 1976, 1977, all to Ciba-Geigy).
  4. ^ http://www.chemspider.com/Chemical-Structure.9312824.html
  5. ^ Liu, Z; Hu, B. H.; Messersmith, P. B. (2010). "Acetonide Protection of Dopamine for the Synthesis of Highly Pure N-docosahexaenoyldopamine". Tetrahedron Letters. 51 (18): 2403–2405. doi:10.1016/j.tetlet.2010.02.089. PMC 2882309Freely accessible. PMID 20543896. 
  6. ^ Crowther, Albert F.; Gilman, D. J.; McLoughlin, B. J.; Smith, Leslie Harold; Turner, R. W.; Wood, T. M. (1969). ".beta.-Adrenergic blocking agents. V. 1-Amino-3-(substituted phenoxy)-2-propanols". Journal of Medicinal Chemistry. 12 (4): 638. doi:10.1021/jm00304a018. PMID 5793156.